NEW YORK (GenomeWeb) – Nuclea Biotechnologies announced today that it has partnered with Aelan Cell Technologies to develop, validate, and commercialize novel biomarker tests and companion diagnostics, with a focus on cancer, metabolic disorders, neurodegeneration, aging, and aging-related disorders.

Nuclea said that the arrangement would combine its expertise in proteomics with Aelan's genomics know-how. Specifically, Nuclea will provide protein analysis of the human stem cells used as models for the tests, while Aelan will provide DNA and mRNA analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.